Current approaches to drug therapy for the hypercholesterolemic patient.
- 1 November 1989
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 80 (5) , 1101-1114
- https://doi.org/10.1161/01.cir.80.5.1101
Abstract
CAD is a complex disease with multiple etiologies and aggravating events. Yet, elevated plasma cholesterol levels, chiefly in the form of LDL, are essential for the progression of the atherosclerotic lesion. Any total plasma cholesterol level above an ideal of 180 mg/dl (and an LDL cholesterol level of 100 mg/dl) must be considered atherogenic in the presence of other risk factors. In patients at high risk for death from CAD, combined diet and drug therapy should have as a goal the attainment of ideal lipoprotein values. Drug therapies are now available that make it possible to substantially lower elevated LDL levels in almost all patients and even to achieve ideal levels in those at highest risk.Keywords
This publication has 39 references indexed in Scilit:
- Beyond CholesterolNew England Journal of Medicine, 1989
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Deletion in the Gene for the Low-Density-Lipoprotein Receptor in a Majority of French Canadians with Familial HypercholesterolemiaNew England Journal of Medicine, 1987
- Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery diseaseThe American Journal of Cardiology, 1986
- Effects of probucol on xanthomata regression in familial hypercholesterolemiaThe American Journal of Cardiology, 1986
- Liver Transplantation to Provide Low-Density-Lipoprotein Receptors and Lower Plasma Cholesterol in a Child with Homozygous Familial HypercholesterolemiaNew England Journal of Medicine, 1984
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Normalization of Low-Density-Lipoprotein Levels in Heterozygous Familial Hypercholesterolemia with a Combined Drug RegimenNew England Journal of Medicine, 1981
- Effects of Neomycin Alone and in Combination with Cholestyramine on Serum Cholesterol and Fecal Steroids in Hypercholesterolemic SubjectsJournal of Clinical Investigation, 1979